Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
The Journal of Urology|February 26, 1999
Changes in free and free-to-total prostate specific antigen after androgen deprivation or chemotherapy in patients with advanced prostate cancerA Berruti, L Dogliotti, G Fasolis, et al.
The Journal of Urology|October 1, 1992
Monoclonal antibody Ki-67 in the study of the proliferative activity of bladder carcinomaD Fontana, M Bellina, L Gubetta, et al.
Cancer|June 22, 2000
Circulating neuroendocrine markers in patients with prostate carcinomaA Berruti, L Dogliotti, A Mosca, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 5, 2002
Potential clinical value of circulating chromogranin A in patients with prostate carcinomaA Berruti, L Dogliotti, A Mosca, et al.
The International Journal of Biological Markers|January 11, 2003
Metabolic effects of single-dose pamidronate administration in prostate cancer patients with bone metastasesA Berruti, L Dogliotti, M Tucci, et al.
BJU International|March 5, 2003
The number of lymph nodes examined and staging accuracy in renal cell carcinomaC Terrone, S Guercio, S De Luca, et al.
European Urology|September 15, 2004
Prognostic value of the involvement of the urinary collecting system in renal cell carcinomaC Terrone, C Cracco, S Guercio, et al.
Endocrine-Related Cancer|March 25, 2005
Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory diseaseA Berruti, A Mosca, M Tucci, et al.
Tumori|June 10, 1998
Randomized comparison of goserelin acetate versus mitomycin C plus goserelin acetate in previously untreated prostate cancer patients with bone metastasesD Fontana, O Bertetto, G Fasolis, et al.
British Journal of Cancer|October 14, 2005
Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone diseaseA Berruti, M Tucci, A Mosca, et al.
Pageof 3